Compare EWTX & WRBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EWTX | WRBY |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 2021 | 2021 |
| Metric | EWTX | WRBY |
|---|---|---|
| Price | $28.57 | $26.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $34.71 | $25.83 |
| AVG Volume (30 Days) | 1.1M | ★ 3.2M |
| Earning Date | 03-02-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | N/A | ★ $850,580,000.00 |
| Revenue This Year | N/A | $15.66 |
| Revenue Next Year | N/A | $12.88 |
| P/E Ratio | ★ N/A | $10,511.07 |
| Revenue Growth | N/A | ★ 14.55 |
| 52 Week Low | $10.60 | $13.63 |
| 52 Week High | $30.48 | $31.00 |
| Indicator | EWTX | WRBY |
|---|---|---|
| Relative Strength Index (RSI) | 56.47 | 51.14 |
| Support Level | $27.07 | $25.25 |
| Resistance Level | $29.98 | $26.98 |
| Average True Range (ATR) | 1.54 | 1.44 |
| MACD | -0.06 | -0.28 |
| Stochastic Oscillator | 61.43 | 31.82 |
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.